To evaluate the potential of pan-LOX inhibition for improving the efficacy of standard therapy for treating iCCA, URCCA4.3 tumor-bearing mice were randomized into cohorts of vehicle, PXS-5505, and weekly doses of FOX with or without PXS-5505. The gene discussed is LOX; the disease is infantile convulsions and choreoathetosis.